Results 201 to 210 of about 216,694 (240)

Metabolic changes in normal-appearing white matter associate with MRI measures of disease burden in relapsing-remitting multiple sclerosis over three years. [PDF]

Sci Rep
Zöchner A, Bogner W, Dal-Bianco A, Strasser B, Hangel G, Rommer PS, Niess E.   +6 more
europepmc   +1 more source

<i>Roseburia</i>-Associated Gut-Brain Axis Alterations in Relapsing-Remitting Multiple Sclerosis: Evidence from a Household-Matched Case-Control Study. [PDF]

Nutrients
Zollo A, Marsiglia MD, Corona A, Ottaviano E, Mazzieri MLT, Mingione A, Ancona S, Priori A, Borghi E, Martinelli-Boneschi F.   +9 more
europepmc   +1 more source

Formulary Restrictions and Relapse Episodes in Persons With Relapsing-Remitting Multiple Sclerosis.

JAMA Netw Open
Blaylock B, Van Nuys K, Joyce G.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial.

Lancet Neurology, 2022
BACKGROUND B-cell depleting therapies are highly efficacious in relapsing-remitting multiple sclerosis but one such therapy, rituximab, is not approved for multiple sclerosis and no phase 3 trial data are available.
A. Svenningsson, T. Frisell, J. Burman, J. Salzer, K. Fink, S. Hallberg, Joakim Hambraeus, M. Axelsson, F. Nimer, P. Sundström, M. Gunnarsson, Rune Johansson, J. Mellergård, I. Rosenstein, Ahmad Ayad, Irina Sjöblom, Anette Risedal, P. de Flon, E. Gilland, J̇onas Lindeberg, F. Shawket, F. Piehl, J. Lycke   +22 more
semanticscholar   +1 more source

Cognitive trajectories in relapsing–remitting multiple sclerosis: A longitudinal 6-year study

Multiple Sclerosis, 2020
Background: Information concerning longitudinal cognitive trajectories in multiple sclerosis (MS) is relatively scarce. Moreover, it is unclear which factors are associated with cognitive decline and what is the clinical impact of cognitive impairment ...
A. Damasceno, L. Pimentel-Silva, B. Damasceno, F. Cendes   +3 more
semanticscholar   +1 more source

Disease-modifying treatments and cognition in relapsing-remitting multiple sclerosis

Neurology, 2020
Objective Disease-modifying treatments (DMTs) are the gold standard for slowing disability progression in multiple sclerosis (MS), but their effects on cognitive impairment, a key symptom of the disease, are mostly unknown.
N. Landmeyer, P. Bürkner, H. Wiendl, T. Ruck, H. Hartung, H. Holling, S. Meuth, A. Johnen   +7 more
semanticscholar   +1 more source

Efficacy of Melatonin on Serum Pro-inflammatory Cytokines and Oxidative Stress Markers in Relapsing Remitting Multiple Sclerosis.

Archives of Medical Research, 2018
Multiple sclerosis (MS) is a chronic inflammatory disease, which leads to focal plaques of demyelination and tissue injury in the central nervous system (CNS).
Angélica L. Sánchez-López, G. Ortiz, F. Pacheco-Moisés, M. Mireles-Ramírez, O. Bitzer-Quintero, D. L. Delgado-Lara, L. J. Ramírez-Jirano, I. E. Velázquez-Brizuela   +7 more
semanticscholar   +1 more source

Prognostic factors of disability in relapsing remitting multiple sclerosis.

Multiple Sclerosis and Related Disorders, 2019
BACKGROUND The clinical manifestation of multiple sclerosis (MS) is highly variable. Factors influencing phenotypic heterogeneity are not well known since most studies have relied on the Expanded Disability Status Scale which has modest inter/intra-rater
F. Briggs, Nicolas R. Thompson, Devon S. Conway   +2 more
semanticscholar   +1 more source

Efficacy and safety of rituximab for relapsing-remitting multiple sclerosis: A systematic review and meta-analysis.

Autoimmunity Reviews, 2019
OBJECTIVE To evaluate the efficacy and safety of rituximab for relapsing-remitting multiple sclerosis. RESULTS Fifteen studies that collectively included 946 patients were selected for the meta-analysis.
Yang Hu, Hao Nie, H. Yu, C. Qin, Long-Jun Wu, Zhouping Tang, Daishi Tian   +6 more
semanticscholar   +1 more source